Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement> ?p ?o ?g. }
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "Similarly, we also need to understand more about the real molecular mechanism of activity of Tocilizumab, a humanized monoclonal antibody." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis (TAK) identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies." provenance.
- Statement label "The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs) is an evolving area." provenance.
- Statement label "The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs) is an evolving area." provenance.
- Statement label "The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs) is an evolving area." provenance.
- Statement label "The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs) is an evolving area." provenance.
- Statement label "The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs) is an evolving area." provenance.
- Statement label "The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs) is an evolving area." provenance.
- Statement label "The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs) is an evolving area." provenance.
- Statement label "There is a paucity of high-quality evidence to guide The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs)." provenance.
- Statement label "There is a paucity of high-quality evidence to guide The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs)." provenance.
- Statement label "There is a paucity of high-quality evidence to guide The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs)." provenance.
- Statement label "There is a paucity of high-quality evidence to guide The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs)." provenance.
- Statement label "There is a paucity of high-quality evidence to guide The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs)." provenance.
- Statement label "Steroids (Methylprednisolone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for the treatment of Cytokine release syndrome (CRS) or cytokine storm in India." provenance.
- Statement label "Steroids (Methylprednisolone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for the treatment of Cytokine release syndrome (CRS) or cytokine storm in India." provenance.
- Statement label "Steroids (Methylprednisolone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for the treatment of Cytokine release syndrome (CRS) or cytokine storm in India." provenance.
- Statement label "Steroids (Methylprednisolone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for the treatment of Cytokine release syndrome (CRS) or cytokine storm in India." provenance.
- Statement label "Steroids (Methylprednisolone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for the treatment of Cytokine release syndrome (CRS) or cytokine storm in India." provenance.
- Statement label "Steroids (Methylprednisolone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for the treatment of Cytokine release syndrome (CRS) or cytokine storm in India." provenance.
- Statement label "Steroids (Methylprednisolone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for the treatment of Cytokine release syndrome (CRS) or cytokine storm in India." provenance.
- Statement label "Steroids (Methylprednisolone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for the treatment of Cytokine release syndrome (CRS) or cytokine storm in India." provenance.
- Statement label "Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality." provenance.
- Statement label "Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality." provenance.
- Statement label "Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality." provenance.
- Statement label "we recommend using alternate equivalent doses of steroids in the event that dexamethasone is unavailable." provenance.
- Statement label "we recommend using alternate equivalent doses of steroids in the event that dexamethasone is unavailable." provenance.
- Statement label "we recommend using alternate equivalent doses of steroids in the event that dexamethasone is unavailable." provenance.
- Statement label "we recommend using alternate equivalent doses of steroids in the event that dexamethasone is unavailable." provenance.
- Statement label "we recommend using alternate equivalent doses of steroids in the event that dexamethasone is unavailable." provenance.
- Statement label "When exploring the effect of the rest of the therapies between groups (affected patients vs unaffected), We found no significant differences in bsDMARD proportions." provenance.